{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T22:07:57Z","timestamp":1788732477607,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"am","delay-in-days":262,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.semarthrit.2025.152773","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:30:31Z","timestamp":1750379431000},"page":"152773","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Two clinical subgroups of immune checkpoint inhibitor-induced inflammatory arthritis determined by latent class analysis"],"prefix":"10.1016","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2795-7059","authenticated-orcid":false,"given":"Laura C.","family":"Cappelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Perin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Zeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifton O.","family":"Bingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami A.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2025.152773_bib0001","article-title":"Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations","author":"Butterfield","year":"2023","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"10.1016\/j.semarthrit.2025.152773_bib0002","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16091619","article-title":"Neoadjuvant and Adjuvant immunotherapy in resectable NSCLC","volume":"16","author":"Bogatsa","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152773_bib0003","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s40257-024-00852-5","article-title":"Rapidly evolving pre- and post-surgical systemic treatment of melanoma","volume":"25","author":"Augustin","year":"2024","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152773_bib0004","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152773_bib0005","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1093\/rheumatology\/kez297","article-title":"Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy","volume":"58","author":"Abdel-Wahab","year":"2019","journal-title":"Rheumatol (Oxf)"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152773_bib0006","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature","volume":"69","author":"Cappelli","year":"2017","journal-title":"Arthritis Care Res (Hob)"},{"key":"10.1016\/j.semarthrit.2025.152773_bib0007","article-title":"Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies","author":"Buder-Bakhaya","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.semarthrit.2025.152773_bib0008","article-title":"Baseline predictors of disease severity in immune checkpoint inhibitor-induced inflammatory arthritis","author":"Cappelli","year":"2023","journal-title":"Rheumatol (Oxf)"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152773_bib0009","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/art.41949","article-title":"Predictors of rheumatic immune-related adverse events and de novo inflammatory arthritis after immune checkpoint inhibitor treatment for cancer","volume":"74","author":"Cunningham-Bussel","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152773_bib0010","article-title":"Checkpoint inhibitor-associated arthritis: a systematic review of case reports and case series","author":"Ghosh","year":"2020","journal-title":"J Clin Rheumatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152773_bib0011","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1136\/ard-2023-223885","article-title":"Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis","volume":"82","author":"Bass","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152773_bib0012","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/annrheumdis-2019-216109","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation","volume":"79","author":"Braaten","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.semarthrit.2025.152773_bib0013","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3899\/jrheum.221182","article-title":"Successful management of checkpoint inhibitor-induced arthritis with disease-modifying antirheumatic drugs during active immune checkpoint inhibition treatment","volume":"50","author":"Brynjarsdottir","year":"2023","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152773_bib0014","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s10067-019-04451-2","article-title":"Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor-induced inflammatory arthritis","volume":"38","author":"Roberts","year":"2019","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152773_bib0015","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s40425-018-0417-8","article-title":"Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series","volume":"6","author":"Moseley","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152773_bib0016","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/rheumatology\/kez361","article-title":"An MRI study of immune checkpoint inhibitor-induced musculoskeletal manifestations myofasciitis is the prominent imaging finding","volume":"59","author":"Daoussis","year":"2020","journal-title":"Rheumatol (Oxf)"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152773_bib0017","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/CJI.0000000000000060","article-title":"Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma","volume":"38","author":"Chan","year":"2015","journal-title":"J Immunother"},{"issue":"12","key":"10.1016\/j.semarthrit.2025.152773_bib0018","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1093\/rheumatology\/kex369","article-title":"Immune checkpoint inhibitor-induced myo-fasciitis","volume":"56","author":"Daoussis","year":"2017","journal-title":"Rheumatol (Oxf)"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152773_bib0019","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.semarthrit.2018.02.011","article-title":"Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen","volume":"48","author":"Cappelli","year":"2018","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152773_bib0020","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41467-022-29539-3","article-title":"Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy","volume":"13","author":"Kim","year":"2022","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152773_bib0021","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/rheumatology\/key358","article-title":"Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis","volume":"58","author":"Cappelli","year":"2019","journal-title":"Rheumatol (Oxf)"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152773_bib0022","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/acr2.11363","article-title":"Patients with checkpoint inhibitor-induced inflammatory arthritis do not become seropositive for anti-cyclic citrullinated peptide when followed over time","volume":"4","author":"Cappelli","year":"2022","journal-title":"ACR Open Rheumatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152773_bib0023","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1001\/jama.2020.2278","article-title":"Using latent class analysis to identify hidden clinical phenotypes","volume":"324","author":"Mori","year":"2020","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.semarthrit.2025.152773_bib0024","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1002\/sim.1105","article-title":"Methods for evaluating the performance of diagnostic tests in the absence of a gold standard: a latent class model approach","volume":"21","author":"Garrett","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.semarthrit.2025.152773_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v042.i10","article-title":"poLCA: an R package for polytomous variable latent class analysis","volume":"42","author":"Linzer","year":"2011","journal-title":"J Stat Softw"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152773_bib0026","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1080\/10705510701575396","article-title":"Deciding on the number of classes in latent class analysis and growth mixture modeling: a Monte Carlo simulation study","volume":"14","author":"Nylund","year":"2007","journal-title":"Struct Equ Model"},{"issue":"440","key":"10.1016\/j.semarthrit.2025.152773_bib0027","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1080\/01621459.1997.10473658","article-title":"Latent variable regression for multiple discrete outcomes","volume":"92","author":"Bandeen-Roche","year":"1997","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.semarthrit.2025.152773_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2018.02.011","article-title":"Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen","author":"Cappelli","year":"2018","journal-title":"Submitt Publ Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152773_bib0029","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13075-025-03546-3","article-title":"Higher levels of VEGF-A and TNF\u03b1 in patients with immune checkpoint inhibitor-induced inflammatory arthritis","volume":"27","author":"Gray-Gaillard","year":"2025","journal-title":"Arthritis Res Ther"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225001441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225001441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T05:59:33Z","timestamp":1780120773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017225001441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":29,"alternative-id":["S0049017225001441"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152773","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Two clinical subgroups of immune checkpoint inhibitor-induced inflammatory arthritis determined by latent class analysis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152773","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152773"}}